The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer

A Budget Impact Analysis in 28 European Countries

L. Gulácsi, Valentin Brodszky, Petra Baji, Fanni Rencz, Márta Péntek

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction: New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. We analyzed the budgetary impact of the introduction of CT-P10 into the European Union (EU) for use in patients with rheumatoid arthritis and cancer diagnoses, using a budget impact analysis model. Methods: The model used a base case scenario in which the 1-year uptake of CT-P10 was estimated at 30%, and the cost of CT-P10 was assumed to be 70% of the cost of RTX. A second 1-year scenario was also modeled, in which the market share of CT-P10 was assumed to be 50% (scenario 2). Finally, 3-year time horizon outcomes were calculated, in which the market share of CT-P10 was assumed to be 30%, 40%, and 50% in the first, second, and third years, respectively. Results: In the base case scenario, the introduction of CT-P10 was associated with projected savings of €90.04 million in the first year, which would allow 7531 additional patients to access rituximab treatment. This was equivalent to a 6.4% increase in the number of rituximab-treated patients. In scenario 2, budget savings were €150.10 million, with a total of 12,551 additional patients able to access rituximab, equivalent to a 10.7% increase. Over a 3-year time horizon, projected budget savings were approximately €570 million, equating to 47,695 additional patients able to access rituximab. Conclusions: The model predicted that the introduction of CT-P10 in the EU will be associated with significant budget savings, the reallocation of which will enable many more patients to access rituximab treatment. This is likely to have a significant impact on health gains at patient and societal levels. Funding: CELLTRION Healthcare Co., Ltd. sponsored the development and analysis of the budget impact analysis model.

Original languageEnglish
Pages (from-to)1128-1144
Number of pages17
JournalAdvances in Therapy
Volume34
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Biosimilar Pharmaceuticals
Rheumatology
Budgets
Neoplasms
European Union
Rheumatoid Arthritis
Costs and Cost Analysis
Rituximab
Cost Savings
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma

Keywords

  • Biosimilar
  • Budget impact analysis
  • Chronic lymphocytic leukemia
  • CT-P10
  • Non-Hodgkin’s lymphoma
  • Rheumatoid arthritis
  • Rheumatology
  • Rituximab

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer : A Budget Impact Analysis in 28 European Countries. / Gulácsi, L.; Brodszky, Valentin; Baji, Petra; Rencz, Fanni; Péntek, Márta.

In: Advances in Therapy, Vol. 34, No. 5, 01.05.2017, p. 1128-1144.

Research output: Contribution to journalArticle

Gulácsi, L. ; Brodszky, Valentin ; Baji, Petra ; Rencz, Fanni ; Péntek, Márta. / The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer : A Budget Impact Analysis in 28 European Countries. In: Advances in Therapy. 2017 ; Vol. 34, No. 5. pp. 1128-1144.
@article{c8932b033e7544bb84f892f9509b2726,
title = "The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries",
abstract = "Introduction: New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. We analyzed the budgetary impact of the introduction of CT-P10 into the European Union (EU) for use in patients with rheumatoid arthritis and cancer diagnoses, using a budget impact analysis model. Methods: The model used a base case scenario in which the 1-year uptake of CT-P10 was estimated at 30{\%}, and the cost of CT-P10 was assumed to be 70{\%} of the cost of RTX. A second 1-year scenario was also modeled, in which the market share of CT-P10 was assumed to be 50{\%} (scenario 2). Finally, 3-year time horizon outcomes were calculated, in which the market share of CT-P10 was assumed to be 30{\%}, 40{\%}, and 50{\%} in the first, second, and third years, respectively. Results: In the base case scenario, the introduction of CT-P10 was associated with projected savings of €90.04 million in the first year, which would allow 7531 additional patients to access rituximab treatment. This was equivalent to a 6.4{\%} increase in the number of rituximab-treated patients. In scenario 2, budget savings were €150.10 million, with a total of 12,551 additional patients able to access rituximab, equivalent to a 10.7{\%} increase. Over a 3-year time horizon, projected budget savings were approximately €570 million, equating to 47,695 additional patients able to access rituximab. Conclusions: The model predicted that the introduction of CT-P10 in the EU will be associated with significant budget savings, the reallocation of which will enable many more patients to access rituximab treatment. This is likely to have a significant impact on health gains at patient and societal levels. Funding: CELLTRION Healthcare Co., Ltd. sponsored the development and analysis of the budget impact analysis model.",
keywords = "Biosimilar, Budget impact analysis, Chronic lymphocytic leukemia, CT-P10, Non-Hodgkin’s lymphoma, Rheumatoid arthritis, Rheumatology, Rituximab",
author = "L. Gul{\'a}csi and Valentin Brodszky and Petra Baji and Fanni Rencz and M{\'a}rta P{\'e}ntek",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s12325-017-0522-y",
language = "English",
volume = "34",
pages = "1128--1144",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "5",

}

TY - JOUR

T1 - The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer

T2 - A Budget Impact Analysis in 28 European Countries

AU - Gulácsi, L.

AU - Brodszky, Valentin

AU - Baji, Petra

AU - Rencz, Fanni

AU - Péntek, Márta

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Introduction: New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. We analyzed the budgetary impact of the introduction of CT-P10 into the European Union (EU) for use in patients with rheumatoid arthritis and cancer diagnoses, using a budget impact analysis model. Methods: The model used a base case scenario in which the 1-year uptake of CT-P10 was estimated at 30%, and the cost of CT-P10 was assumed to be 70% of the cost of RTX. A second 1-year scenario was also modeled, in which the market share of CT-P10 was assumed to be 50% (scenario 2). Finally, 3-year time horizon outcomes were calculated, in which the market share of CT-P10 was assumed to be 30%, 40%, and 50% in the first, second, and third years, respectively. Results: In the base case scenario, the introduction of CT-P10 was associated with projected savings of €90.04 million in the first year, which would allow 7531 additional patients to access rituximab treatment. This was equivalent to a 6.4% increase in the number of rituximab-treated patients. In scenario 2, budget savings were €150.10 million, with a total of 12,551 additional patients able to access rituximab, equivalent to a 10.7% increase. Over a 3-year time horizon, projected budget savings were approximately €570 million, equating to 47,695 additional patients able to access rituximab. Conclusions: The model predicted that the introduction of CT-P10 in the EU will be associated with significant budget savings, the reallocation of which will enable many more patients to access rituximab treatment. This is likely to have a significant impact on health gains at patient and societal levels. Funding: CELLTRION Healthcare Co., Ltd. sponsored the development and analysis of the budget impact analysis model.

AB - Introduction: New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. We analyzed the budgetary impact of the introduction of CT-P10 into the European Union (EU) for use in patients with rheumatoid arthritis and cancer diagnoses, using a budget impact analysis model. Methods: The model used a base case scenario in which the 1-year uptake of CT-P10 was estimated at 30%, and the cost of CT-P10 was assumed to be 70% of the cost of RTX. A second 1-year scenario was also modeled, in which the market share of CT-P10 was assumed to be 50% (scenario 2). Finally, 3-year time horizon outcomes were calculated, in which the market share of CT-P10 was assumed to be 30%, 40%, and 50% in the first, second, and third years, respectively. Results: In the base case scenario, the introduction of CT-P10 was associated with projected savings of €90.04 million in the first year, which would allow 7531 additional patients to access rituximab treatment. This was equivalent to a 6.4% increase in the number of rituximab-treated patients. In scenario 2, budget savings were €150.10 million, with a total of 12,551 additional patients able to access rituximab, equivalent to a 10.7% increase. Over a 3-year time horizon, projected budget savings were approximately €570 million, equating to 47,695 additional patients able to access rituximab. Conclusions: The model predicted that the introduction of CT-P10 in the EU will be associated with significant budget savings, the reallocation of which will enable many more patients to access rituximab treatment. This is likely to have a significant impact on health gains at patient and societal levels. Funding: CELLTRION Healthcare Co., Ltd. sponsored the development and analysis of the budget impact analysis model.

KW - Biosimilar

KW - Budget impact analysis

KW - Chronic lymphocytic leukemia

KW - CT-P10

KW - Non-Hodgkin’s lymphoma

KW - Rheumatoid arthritis

KW - Rheumatology

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85020581561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020581561&partnerID=8YFLogxK

U2 - 10.1007/s12325-017-0522-y

DO - 10.1007/s12325-017-0522-y

M3 - Article

VL - 34

SP - 1128

EP - 1144

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 5

ER -